Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport

Xenobiotica

Volumn 35, Issue 7, 2005, Pages 737-753

  Yamazaki, M ^a   Li, B ^a   Louie, S W ^a   Pudvah, N T ^a   Stocco, R ^b   Wong, W ^b   Abramovitz, M ^b   Demartis, A ^c   Laufer, R ^c   Hochman, J H ^a   Prueksaritanont, T ^a   Lin, J H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^c IRBM   (Italy)

Author keywords

Drug drug interactions; Fibrates; Liver; MRP2; OATP; P gp

Indexed keywords

BEZAFIBRATE; CIMETIDINE; CLOFIBRATE; CLOFIBRIC ACID; CYCLOSPORIN A; ESTRADIOL; ETACRYNIC ACID; FENOFIBRATE; FENOFIBRIC ACID; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUTATHIONE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1B1; UNCLASSIFIED DRUG; VERLUKAST;

ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG TRANSPORT; DRUG UPTAKE; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; INSECT CELL; MEMBRANE VESICLE; NONHUMAN; PLASMA PROTEIN BINDING;

ANTILIPEMIC AGENTS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE; CLOFIBRIC ACID; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; ESTRADIOL; HUMANS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORT POLYPEPTIDE C; P-GLYCOPROTEIN;

EID: 26644438110     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250500136676     Document Type: Article

References (44)

1. Abshagen U, Spörl-Radun S, Marinow J. 1980. Steady-state kinetics of bezafibrate and clofibrate in health female volunteers. Eur J Clin Pharmacol 17:305-308.
2. Adkins JC, Faulds D. 1997. Micronised fenofibrate. A review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 54:615-633.
3. Alsheikh-Ali AA, Kuvin JT, Karas RH. 2004. Risk of adverse events with fibrates. Am J Cardiol 94:935-938.
4. Backman JT, Kyrklund C, Kivistö KT, Wang J-S, Neuvonen PJ. 2000. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68:122-129.
5. Backman JT, Kyrklund C, Neuvonen M, Neuvonen PJ. 2002. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691.
6. Bergman AJ, Murphy G, Burks J, Zhao J, Valesky R, Liu L, Lasseter KC, He W, Prueksaritanont T, Qiu Y, Hargford A, Vega JM, Paolini JF. 2004. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 44:1054-1062.
7. Chen Z-A, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. 2003. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ACC10). Mol Pharmacol 63:351-358.
8. Chu X-Y, Huskey Su-EW, Braun MP, Sarkadi B, Evans DC, Evers R. 2004. Transport of ethinylestradiol glucuronide and ethinylestradiol sulfate by the multidrug resistance proteins MRP1, MRP2, and MRP3. J Pharmacol Exp Ther 309:156-164.
9. Ehrhardt M, Lindenmaier H, Burhenne, Haefeli WE, Weiss J. 2004. Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem Pharmacol 67:285-292.
10. Fehrenbach T, Cui Y, Faulstich H, Keppler D. 2003. Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins. Naunyn-Schmiedeberg's Arch Pharmacol 368:415-420.
11. Gugler R, Krüten JW, Jensen CJ, Klehr U, Hartlapp J. 1979. Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol 15:341-347.
12. Hagmann W, Schubert J, Konig J, Keppler D. 2002. Reconstitution of transport-active multidrug resistance protein 2 (MRP2; ABCC2) in proteoliposomes. Biol Chem 383:1001-1009.
13. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2004. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311:139-146.
14. Hochman JH, Pudvah NT, Qiu J, Yamazaki M, Tang C, Lin JH, Prueksaritanont T. 2004. Interactions of human P-glycoprotein with simvastatin, simvastatin acid, and atorvastatin. Pharm Res 21:1688-1693.
15. Hsiang B, Zhu Y, Wang Z, Wu Y, Sasseville V, Yang WP, Kirchgessner TG. 1999. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 274:37161-37168.
16. Kajosaari LJ, Backman JT, Nuevonen M, Laitila J, Neuvonen PJ. 2004. Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. Br J Pharmacol 58:390-396.
17. Kivistö KT, Zunkunft J, Hofmann U, Niemi M, Rekersbring S, Schneider S, Luippold G, Schwab M, Eichelbaum M, Fromm MF. 2004. Characterisation of cerivastatin as a P-glycoprotein substrate: Studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice. Naunyn-Schmiedeberg's Arch Pharmacol 370:124-130.
18. Kusuhara H, Sugiyama Y. 2001. Drug-drug interactions involving the membrane transport process. In: Rodrigues AD, editor. Drug-drug interactions. Basel: Marcel Dekker. pp 123-188.
19. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. 2001. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 69:340-345.
20. Kyrklund C, Backman JT, Neuvonen M, Neuvonen PJ. 2003. Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance. Clin Pharmacol Ther 73:538-544.
21. Leier I, Jedlitschky G, Buchholz U, Coles SPC, Deeley RG, Keppler D. 1997. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 269:27807-27810.
22. Martin PD, Dane AL, Schneck DW, Warwick MJ. 2003. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 25:459-471.
23. Miller DB, Spence JD. 1998. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34:155-162.
24. Monk JP, Todd PA. 1987. Bezafibrate: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 33:539-576.
25. Pan W-J, Gustavson LE, Achari R, Rieser MJ, Ye X, Gutterman C, Wallin BA. 2000. Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol 40:316-323.
26. Prueksaritanont T, Richards KM, Qiu Y, Strong-Basalyga K, Miller A, Li Chunze, Eisenhandler R, Carlini DJ. 2005. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharm Res 22:71-78.
27. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Un JH. 2002a. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30:1280-1287.
28. Prueksaritanont T, Zhao JJ, Ma B, Roadcap BA, Tang C, Qiu Y, Liu L, Lin JH, Pearson PG, Baillie TA. 2002b. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301:1042-1051.
29. Sasaki M, Suzuki H, Ito K, Abe T, Sugiyama Y. 2002. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP/ABCC2). J Biol Chem 277:6497-6503.
30. Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. 2004. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 75:455-463.
31. Sedaghat A, Ahrens EH. 1975. Lack of effect of cholestyramine on the pharmacokinetics of Clofibrate in man. Eur J Clin Invest 5:177-185.
32. Shitara Y, Hirano M, Sato H, Sugiyama Y. 2004. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1: SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: Analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J Pharmacol Exp Ther 311:228-236.
33. Shitara Y, Itoh T, Sato H, Li AP, Sugiyama Y. 2003. Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A. J Pharmacol Exp Ther 304:610-616.
34. Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CDA, Windass AS, Schneck DW. 2004. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 76:167-177.
35. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. 1995. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 76:80A-83A.
36. Tamai I, Nozawa T, Koshida M, Nezu J, Sai Y, Tsuji A. 2001. Functional characterization of human organic anion transporting polypeptide B (OATP-B) in comparison with liver-specific OATP-C. Pharm Res 18:1262-1269.
37. Todd PA, Ward A. 1988. Gemfibrozil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in dyslipidaemia. Drugs 36:314-339.
38. Wang J-S, Neuvonen M, Wen X, Backman JT, Neuvonen PJ. 2002. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 30:1352-1356.
39. Wen X, Wang J-S, Backman JT, Kivistö KT, Neuvonen PJ. 2001. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 29:1359-1361.
40. Wu X, Whitfield LR, Stewart BH. 2000. Atorvastatin transport in the Caco-2 cell model: Contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res 17:209-215.
41. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. 1981. A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharm Dyn 4:879-885.
42. Yamazaki M, Akiyama S, Ni'inuma K, Nishigaki R, Sugiyama Y. 1996. Biliary excretion of pravastatin in rats: Contribution of the excretion pathway mediated by canalicular multispecific organic anion transporter (cMOAT). Drug Metab Disposit 25:1123-1129.
43. Yamazaki M, Neway WE, Ohe T, Chen I-Wu, Rowe JF, Hochman JH, Chiba M, Lin JH. 2001. In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predictability of in vivo results. J Pharmacol Exp Ther 296:723-735.
44. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. J Pharmacol Exp Ther 264:G36-44.